The Horizon report is based on survey responses from more than 500 industry leaders who provide insight into all corners of the industry. The investigation of cell and gene therapies is proving to be a disruptive space that is reshaping biopharma business models. When cell therapies first went into human testing, Walters said the big question on the minds of the scientists was, “will it work?”
Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.